Medical/Pharmaceuticals
Trajan to acquire LEAP PAL Parts
MELBOURNE, Australia, Dec. 9, 2021 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has entered into a binding agreement to acquire the business of LEAP PAL Parts and Consumables, LLC ("LPP"), based in Raleigh North Caro...
2021-12-09 21:00
3048
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma
SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at8:00 a.m. EST o...
2021-12-09 21:00
2367
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan
SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...
2021-12-09 08:00
3223
Novalis LifeSciences Launches its Second Life Science Investment Fund with $300M and announces key new team members.
HAMPTON, N.H., Dec. 8, 2021 /PRNewswire/ -- Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry, announced today that is has raised$300M in capital for its second fund – Novalis LifeSciences Investments II, LP. In addition,Paul M. Meister has joined the firm as...
2021-12-09 00:00
2108
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient had been dosed in the I-Mab and Nh...
2021-12-08 21:00
3784
Nippon Express (Nederland) Acquires GDP Compliance Certification for Company-owned Warehouse
TOKYO, Dec. 8, 2021 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NEN"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification, effectiveSeptember 6, for its company-owned warehouse in Schiphol Trade Park nearAmsterdam's Schiphol ...
2021-12-08 14:00
2116
China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again
ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening
Ceremony ofGenScript ProBio
2021-12-07 21:33
2364
Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting
HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...
2021-12-07 21:32
3347
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") ...
2021-12-07 21:00
5217
SyMap Medical Ltd. Closes Largest Financing Round in Renal Denervation Field
SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- SyMap Medical (SyMap) announced its latest financing round of nearly$100 million led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China. CEC Capital served as the exclusive...
2021-12-07 20:30
2852
Samsung Biologics adds to global ISO certifications with Quality Management System
* Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle * The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, a...
2021-12-07 13:04
2740
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendo...
2021-12-07 08:20
2671
IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy
SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) successfully took place inShanghai on December 3rd (GMT+8). With the theme of "Synthetic Lethality: A New Platform for Targeted Therapy", the event attracted nearly 300 guests offline and online. The gues...
2021-12-06 16:03
2486
Odyssey Announces Agreement to Combine with BenevolentAI
* BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines * Combination of BenevolentAI with Odyssey, a €300m Euronext Amsterdam-listed special purpo...
2021-12-06 14:00
11270
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...
2021-12-06 09:16
3198
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...
2021-12-04 21:00
5543
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...
2021-12-03 21:00
4195
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science
SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").Zili Li, M...
2021-12-03 17:01
6268
Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies
ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...
2021-12-03 16:23
2497
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...
2021-12-03 10:13
2814
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 299 media titles]
2026-08-25 10:00Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
[Picked up by 291 media titles]
2026-08-25 07:00
ViewSonic Launches XG2738-2K-OLED Gaming Monitor with QD-OLED Technology and OLED Care
[Picked up by 288 media titles]
2026-08-27 10:30
Most Read
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
19398
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
15010